How the budgets for the development of medicine are mastered in Russia. And why does it all end with arrests and not new drugs?
Back in the late 2000s, before the sanctions and the policy of import substitution that followed, Russia began to develop a state program for the development of the medical industry, called Pharma-2020. Its goals are to create its own medicines, the share of which on the domestic market should be at least 50%, as well as to transfer successful Western pharmaceutical technologies to Russia. The project is supervised by the Ministry of Industry and Trade, billions of rubles have been invested in it.
By the end of the program, it turned out that the budget funds had not been fully utilized, and those that were mastered were spent without significant benefit. Of the 57 drugs that were planned to be transferred from abroad, only four were put into production. In addition, the investigating authorities reported major fraud during the program. On suspicion of him, officials of the ministry Olga Pokidysheva and Olga Kolotilova, as well as a member of the Russian Olympic Committee, Alexei Vlasenko, have now been detained. Despite this, “Pharma-2020” was extended for another three years.
In the Text of the Week podcast, the authors of the Pharma 2020 investigation , Meduza special correspondents Svetlana Reiter and Ivan Golunov talk about how the pharmaceutical business is organized in Russia at state expense and why this seemingly unsuccessful project can still be useful. for example, in the production of domestic vaccines.